Should you buy CSL and ResMed shares in January?

Let's see what one leading broker is saying about these blue chips.

| More on:
Six smiling health workers pose for a selfie.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) shares are popular blue chip options for investors.

But are they in the buy zone right now?

Let's take a look at what one leading broker is saying about these high-quality companies in January.

Are CSL shares a buy?

According to a note out of Goldman Sachs, its analysts think that investors should snap up this biotherapeutics giant's shares before they rally.

After several years of underperformance, the broker believes that the company is destined to deliver strong earnings growth through to FY 2028. It said:

Our Buy thesis is driven by (1) Double digit IG growth (GSe: +12.6% FY23-FY28E CAGR) underpinned by low penetration (including CIDP) and ~100bps YoY market share gains. Our channel checks indicate CSL's competitive advantages are intact, with the expansion in fractionation capacity set to enhance CSL's superior cost profile and supply reliability, (2) Strong Gross Margin (GM%) recovery with Behring plasma collection costs per liter set to meaningfully decline (-14.6% FY26E vs FY24), and (3) Rebound in Seqirus growth from depressed US influenza vaccination rates.

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over the next 12 months.

What about ResMed shares?

Goldman also thinks that sleep disorder treatment company ResMed would be a great option for investors right now.

It is bullish on the blue chip due to its huge market opportunity, potential market share gains, and expanding margins. It said:

Our Buy thesis is underpinned by (1) Robust Continuous Airway Pressure Therapy (CPAP) patient growth assisted by growing awareness on Obstructive Sleep Apnea (OSA), (2) Market share gains, particularly in OSA masks and (3) Operating margin expansion driven by product mix and solid cost management.

Goldman also points out that it believes weight loss wonder drugs are not to be feared. It adds:

We believe GLP-1 drugs to treat OSA will co-exist with CPAP therapy based on the published clinical data and payor policies to date. Engagement on RMD's patient app (myAir) indicates ongoing momentum in therapy compliance, noting the potential of the rate of OSA diagnosis to step up from Zepbound's (GLP-1 drug from LLY) Medicare's coverage.

The broker has a buy rating and $48.90 price target on ResMed's shares. Based on its current share price of $38.84, this implies potential upside of approximately 26% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

Morgans says these ASX 200 blue chip shares are buys

Let's see which blue chips the broker is recommending to clients.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Blue Chip Shares

3 super strong ASX 200 blue chip shares to buy now

These blue chips have been given a big thumbs up by brokers.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Blue Chip Shares

Buy these fantastic ASX shares for your SMSF

Looking to bolster your self-managed super fund? Then check out these buy-rated shares.

Read more »

A woman standing in a blue shirt smiles as she uses her mobile phone.
Blue Chip Shares

2 ASX blue-chip shares that I think are excellent long-term buys

I think these blue-chip shares are impressive players.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

These top blue chip ASX 200 shares could rise 25% to 75%

Brokers are tipping these shares to deliver big returns over the next 12 months.

Read more »

A man thinks very carefully about his money and investments.
Blue Chip Shares

2 super ASX 200 blue chip shares to buy now

Brokers are saying good things about these stocks. Let's see why.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Blue Chip Shares

3 unstoppable ASX 200 shares to buy and hold for 10+ years

Analysts are tipping these shares to deliver strong returns. But why?

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Blue Chip Shares

If I were building a portfolio from scratch, I'd buy these 3 ASX 200 shares today

These quality shares could be great picks for investors building a portfolio.

Read more »